Gene-directed enzyme prodrug therapy is a promising approach to the local management of cancer and a number of gene prodrug combinations have entered clinical trials. The antitumor activity of Escherichia coli nitroreductase (NTR) in combination with the prodrug CB1954 relies on the reduction of the nitro groups to reactive N-hydroxylamine intermediates that are toxic in proliferating and nonproliferating cells. We examined whether secondary metabolic activation of the N-hydroxylamines by sulfotransferases or acetyltransferases altered cell responsiveness to the drug. We evaluated the coexpression of NTR with the human cytosolic sulfotransferases SULT1A1, 1A2, 1A3, 1E1 and 2A1, or the human arylamine N-acetyltransferases NAT1 and NAT2 on SKOV3 cell survival. Only NAT2 significantly altered the toxicity of CB1954, decreasing the IC 50 16-fold from 0.61 to 0.04 mM. These results suggest that one or more of the N-hydroxyl metabolites are a substrate for O-acetylation by NAT2. We also examined the bystander effect of SKOV3 cells expressing NTR or NTR plus NAT2. Addition of the acetyltransferase resulted in a significant decreased bystander effect (P40.01), possibly due to a lower concentration of reactive metabolites in the culture medium. These results suggest that a combination of bacterial NTR and NAT2 may provide a greater clinical response at therapeutic concentrations of CB1954 provided the reduction in bystander effect is not clinically significant. Moreover, endogenous NAT2, which is localized predominantly in the liver and gut, may be involved in the dose-limiting hepatic toxicity and gastrointestinal side effects seen in patients treated with the higher doses of CB1954.
Introduction
Enzyme prodrug combinations have emerged as a novel approach for the treatment of a variety of cancers. Genedirected enzyme prodrug therapy (GDEPT) is a suicide gene therapy that targets a gene encoding a prodrugactivating enzyme to tumour cells usually using a viral delivery system. 1, 2 Expression of the exogenous enzyme leads to the local conversion of a nontoxic prodrug to a cytotoxic metabolite, followed by preferential tumour cytotoxicity. One GDEPT system that has progressed to phase I clinical trials is the nitroreductase (NTR)-CB1954 (5-(aziridin-1-yl)-2,4-dinitro-benzamide) combination. 3 The Escherichia coli NTR gene nfnB/nfsB encodes an oxygen-insensitive flavin mononucleotide-dependent enzyme that in the presence of nicotinamide adenine dinucleotide (phosphate) oxidase (NAD(P)H) activates CB1954 to generate potent DNA cross-linking intermediates that can induce apoptosis in both dividing and nondividing cells. 4, 5 CB1954 is converted to a mixture of 2-and 4-hydroxylamines 6 of which the 4-hydroxylamine is the more cytotoxic of the two metabolites. 7 The NTR/ CB1954 combination was originally an attractive therapy for tumour treatment because the only human enzyme thought to substantially activate CB1954 was DTdiaphorase (NAD(P)H dehydrogenase), a flavoprotein that catalyzes the two-electron reduction of quinones. This human enzyme is much less efficient in reducing CB1954 than the E. coli NTR. 6, 8 More recently, however, a number of hepatic enzymes have been shown to bioactivate the drug. 9 This may be important for the hepatic toxicity seen in phase I clinical trials using CB1954 and NTR. 3 The esterification of N-hydroxylamines is thought to be an important activation step for many arylamine and heterocyclic amine carcinogens. 10, 11 In particular, O-sulfonation and O-acetylation have been shown to markedly increase DNA binding and mutagenesis of these classes of carcinogens. Nonenzymatic reaction of the N-hydroxyl intermediates with acetylcoenzyme A to generate the DNA cross-linking N-acetoxy hydroxylamine metabolites has been also reported. 12 However, the possibility that one or both intermediates are substrates for sulfotransferase or N-acetyltransferase activation has not been studied. Enzymatic esterification of the N-hydroxyl intermediates of CB1954 may significantly increase sensitivity of cancer cells to the prodrug. In this report, we have coexpressed a number of human sulfotransferases and N-acetyltransferases with NTR in SKOV3 cells and then examined the cytotoxicity and bystander effect of CB1954. The results show that NAT2 can markedly enhance the cytotoxicity of the drug, possibly by secondary activation of the hydroxylamine metabolites following nitroreduction.
Materials and methods

Construction of expression plasmids
The coding sequence of human SULTs was amplified by PCR from pEF-SULT1A1, 1A2, 1A3, 1E1 and 2A1 constructs using the following primers; SULT1A1, 1A2 and 1A3 were generated using the common forward and reverse primers:
0 -GGTACCGGTACCAATGAATTCTGAACT TGAC-0 3 (Kpn1) and reverse primer 3 0 -TCTAGATCTA GATTAGATCTCAGTTCGAAAC-0 5 (Xba1). SULT2A1 forward primer 5 0 -GGTACCGGTACCAATGTCGGAC GATTTCTTATG-0 3 (Kpn1) and reverse primer 3 0 -TCTA GATCTAGATTATTCCCATGGGAACAGC-0 5 (Xba1). The FLAG tagged NAT1 construct was generated as described previously. 13 The NAT2 FLAG-tagged construct was created as follows. The NAT2 coding sequence was amplified using DNA from an individual who had a NAT2*4 genotype and the following primers; 5 0 -TCCG GAATTCAATGGACATTGAAGC-0 3 (EcoR1) and reverse primer 3 0 -GTTCCGATATCTAAATAGTAAGGG ATCCATCACCAGG TTTGGGCACGAG-0 5 (EcoRV). The resulting fragments were then cloned in-frame into the mammalian expression vector p3xFLAG-CMV-7.1 (Sigma-Aldrich, Castle Hill, NSW, Australia).
Cell culture
The human ovarian carcinoma SKOV3 and stable NTRexpressing SKOV3 (SKOV3-NTR) cell lines were generously donated by Dr Peter F Searle, University of Birmingham. The SKOV3-NTR cell line has been described previously.
14 Both cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS). Medium for the NTRexpressing cell-line was supplemented with 300 mg ml À1 G418. Cell cultures were incubated in a humidified atmosphere of 5% CO 2 /95% air at 37 1C. All cultures were free from Mycoplasma infection.
Generation of SULT and NAT stable cell lines
To obtain stable transfection, SKOV3-NTR cells were transfected with 1 mg of pFLAG SULT or NAT construct and vector alone without insert for mock control. Transfection of SKOV3-NTR cells was performed using Lipofectamine 2000 (Invitrogen, Mount Waverley, VIC, Australia) according to the manufacturer's instructions. Briefly, SKOV3-NTR cells were seeded in 12-well plates at a density of 2 Â 10 5 cells per well and, 24 h later, cotransfected with 50 ng pTKHyg (Clontech, Mountain View, CA, USA) and 1 mg of linearized pFLAG vector alone, pFLAG-NAT1 or pFLAG-NAT2 constructs. Cells were incubated for 24 h and then trypsinized and plated in 25 cm 2 flasks. After 48 h the SKOV3-NTR cells were cultured in selection medium containing 300 mg ml À1 G418 and 500 mg ml À1 hygromycin. After selection for 7 days, transfected cells were maintained in medium containing 300 mg ml À1 G418 and 300 mg ml À1 hygromycin.
Cell lysate preparation
Cells were washed twice with phosphate-buffered saline (PBS), resuspended in buffer (20 mM Tris (pH 7.4), 1 mM EDTA, and 1 mM DTT), and lyzed on ice by sonication. Cell lysates were then centrifuged at 4 1C and the supernatant used immediately for NAT activity as previously described 15 or stored at À30 1C for western blot analysis.
Western blot analysis
Cells were washed once in PBS and harvested by scraping in PBS. Pellets were lyzed on ice by sonication. Total cell lysate was separated on 12% SDS-polyacrylamide gels, transferred to nitrocellulose and immunoblotted using mouse anti-FLAG M2-peroxidase conjugate antibody (Sigma-Aldrich).
CB1954 cytotoxicity assay
Cells were plated at 2 Â 10 4 cells per well in a 96-well plate and allowed to attach overnight. The following day the media were removed and CB1954 in 100 ml culture media was added to each well. CB1954 was dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich) at 40 mM and further diluted in culture medium. Cells were incubated in CB1954 for 24 h after which the medium was replaced and the cells cultured in the absence of drug to a total time of 48 h. Cell survival was determined by the Celltiter96 Aqueous assay (Promega) and the data were expressed as percent of vehicle-treated controls.
Fluorescent cell labeling
The SKOV3-NTR cell membranes were labeled with fluorescent stain PKH 67 (Sigma-Aldrich) as per manufacturer's instructions. Briefly, 1 Â 10 7 cells were suspended in 100 ml of Diluent C, and stained by rapidly admixing with 100 ml of 4 mM working PKH67 solution, prepared by diluting 10 À3 M ethanolic dye stock in diluent C immediately prior to staining. Staining was stopped after 5 min by addition and incubation with 200 ml of FCS for 1 min. Cells were washed three times with 10 ml of DMEM containing 10% FCS. Labeled SKOV3-NTR cells were then seeded at various ratios with unlabeled SKOV3 to a total cell number of 1 Â 10 5 cells in a 24-well plate. The following day, cells were treated with 100 mM CB1954 for 24 h after which the medium was removed and the cells incubated in fresh medium for another 24 h. After a total incubation time of 48 h, cells were washed with PBS and removed by trypsinization. Cells were diluted in PBS and subjected to analysis by flow cytometry.
Flow cytometry
Mean fluorescence intensity was measured using a FACSCanto flow cytometer (BD Biosciences
Data analysis
All data are presented as the mean and standard errors. Estimates of the IC 50 values for each dose-response curve was obtained by fitting a sigmoidal curve to the data by nonlinear least-squares regression analysis without data weighting using Prism 4 (GraphPad software). The bystander effects were compared by a two-way analysis of variance (ANOVA). Figure 1a outlines the known metabolic activation pathway for CB1954 9 and includes the proposed secondary metabolism of the hydroxylamines. Reduction of the drug is obligatory for cytotoxicity. Consequently, SKOV3 cells stably transfected with NTR showed a decrease in the IC 50 for CB1954 from over 100 mM to less than 1 mM (Figure 1b) .
Results and discussion
Sulfonation of hydroxylamines to sulfate esters has been demonstrated for a number of procarcinogens. 16 The highly unstable esters decompose to electrophilic nitrinium ions that alkylate cellular macromolecules and other nucleophiles. To test whether any of the major human sulfotransferases can activate CB1954 metabolites, stably transfected SKOV3-NTR cells expressing various SULT genes (SULT1A1, 1A2, 1A3, 1E1 and 2A1) were generated. The different sulfotransferases exhibit different substrate specificities as well as tissue distribution.
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SULT1A1 and 1A2 metabolize simple phenolic compounds such as p-nitrophenol and paracetamol as well as several carcinogens. SULT1A3 can metabolize endogenous catecholamine, dopamine and norepinephrine. By contrast, SULT1E1 is involved in the sulfonation of estrogens whereas SULT 2A1 can metabolize other steroids.
Expression of the different sulfotransferases was confirmed by western blots of the FLAG-tagged proteins (Figure 2a) . The cytotoxicity of CB1954 was similar in the presence and absence of each sulfotransferase (Figure 2b ) with the exception of SULT2A1 where the IC 50 for the drug increased from 1.1 to 2.7 mM. These results suggest that if the N-hydroxylamine intermediates of CB1954 are sulfonated by any of these sulfotransferases the resulting esters do not affect cytotoxicity.
The second major pathway for esterification of N-hydroxylamines involves O-acetylation catalyzed by one of two possible acetyltransferases expressed in humans, NAT1 or NAT2. Although NAT1 is found in most tissues of the body, NAT2 is primarily localized to the liver and gastrointestinal tract. 18 Expression of the respective N-acetyltransferases in stable SKOV3-NTR cells was demonstrated by western blot (Figure 2c ). In addition, enzyme activity was determined using the model substrates p-aminobenzoic acid and sulfamethazine for NAT1 and NAT2, respectively, which confirmed the western blots. In cells transfected with NAT1, activity increased from 6.2±0.1 to 487±12 nmol min À1 mg
À1
protein. NAT2 is not constitutively expressed in SKOV3 cells, so activity increased from undetectable levels to 1.7 ± 0.1 nmol min À1 mg À1 protein. The cytotoxicity of CB1954 was not affected by NAT1 (Figure 2d ) whereas NAT2 significantly decreased the IC 50 of the drug 16-fold from 0.61 mM (95% CI ¼ 0.50-0.74 mM) to 0.04 mM (95% CI ¼ 0.03-0.05 mM). At a drug concentration as low as 0.1 mM, the percent viable SKOV3-NTR cells after 48 h was greater than 95%. For the SKOV3-NTR cells coexpressing NAT2, the percent viable cells was less than 20%. This concentration is much less than that seen in patients treated with CB1954. 3 Thus, coexpression of NTR and human NAT2 can significantly increase response to the drug. Taken together, these results suggest that one or both of the N-hydroxylamine intermediates are further metabolized by NAT2 to a highly reactive N-acetoxy product (Figure 1a) .
The generation of cytotoxic metabolites capable of killing neighboring cells that do not express an activation enzyme is crucial to the success of any GDEPT system for cancer treatment. For CB1954, the N-hydroxylamine metabolites are sufficiently stable and lipophilic to freely diffuse away from their site of production 19 and a bystander effect for this system has been clearly established. 20 As the N-acetoxy metabolites of arylamines are highly reactive with short lifetimes in biological systems, 10, 21 their ability to diffuse across biological membranes is much reduced. Therefore, the effect of coexpressing NTR and NAT2 on CB1954 bystander was examined. In these studies, the drug was tested at 100 mM as this concentration was cytotoxic to more than 99% of SKOV3-NTR cells but was essentially nontoxic in the parental SKOV3 cells (Figure 1b) .
To confirm that the SKOV3-NTR (activator) cells retained their sensitivity to CB1954 in a mixed cell population, they were fluorescently labeled and then cocultured with unlabeled SKOV3 (target) cells. Flow cytometry showed that the two populations of cells could be distinguished by the weak autofluorescence of the parental cells (Figure 3a, upper panel) and the much stronger fluorescence of the labeled SKOV3-NTR cells (Figure 3a, middle panel) . In addition, the SKOV3-NTR cells showed greater than 99% cell death compared to the SKOV3 cells (Figure 3a, right panels) . When a mixed population of the two cell lines (50% SKOV3 and 50% SKOV3-NTR) was treated with 100 mM CB1954 for 48 h, none of the SKOV3-NTR cells was Figure 1 (a) Metabolic activation pathway of CB1954 by nitroreductase. The 2-and 4-hydroxylamines are electrophilic intermediates capable of alkylating cellular nucleophiles including DNA. These metabolites can undergo further reduction to the respective amines. Acetylation or sulfation of the N-hydroxyl groups can generate highly reactive esters that dismutate to nitrinium ions. 10 Adapted in part from Tang et al. 9 (b) Effect of nitroreductase (NTR) on CB1954 cytotoxicity. SKOV3 cells (K) and SKOV-NTR cells (J) were cultured in the presence of increasing concentration of CB1954. Cell viability was determined after 48 h. Data are the mean ± s.e.m., n ¼ 8.
detectable indicating complete cell death (Figure 3a , lower right panel), confirming their selective sensitivity to the drug. Figure 3b shows the number of viable cells for various ratios of activator and target cells following CB1954 treatment. At 85% target cells, less than 50% of the total cells were viable after 48 h (open bars). If no bystander effect was evident, the expected cell number would be 85% of controls. Therefore, significant target cell toxicity occurred (two-way ANOVA, P40.01). A similar bystander effect was seen with 75 and 50% target cells. When the activator cells were replaced with SKOV3-NTR cells expressing NAT2 (closed bars), the bystander effect was much weaker at all target to activator ratios studied. These results suggest that although some evidence of target cell death was still apparent when human NAT2 was included, it was much less than without the N-acetyltransferase. One possible explanation for this observation is the greater reactivity of the acetoxy intermediates, which may reduce the concentration of 2-and 4-hydroxylamines excreted into the culture medium.
The present study has shown that the combination of bacterial NTR and human NAT2 dramatically increased the sensitivity of cells to the prodrug CB1954, suggesting that coexpression of the two genes that encode these enzymes may significantly enhance responsiveness to CB1954 treatment. Clinically, this may be an advantage as the drug dose may be reduced without loss of efficacy. However, a decrease in bystander seen in the in vitro model used in the present study may negatively impact on any clinical effectiveness of combining NAT2 and NTR. Nevertheless, some evidence of bystander still remained (Figure 3b ). Further work using animal models is required to establish whether the decrease in bystander effect negates the potential benefit of combining these two enzymes in a GDEPT approach for cancer treatment. Other approaches have been attempted to enhance biological responsiveness to CB1954 and its analogues. One promising advance involved enhancement of the catalytic activity of the NTR using site-directed mutagenesis. 22 In particular, the F124K NTR mutant reportedly showed a fivefold increase in sensitivity to the drug.
The potential role of NAT2 in CB1954 metabolism may, in part, explain the liver-and gastrointestinalspecific toxicity seen in clinical trials, as NAT2 is predominantly expressed in these tissues. 23, 24 A recent study has shown that human liver can reduce CB1954 to N-hydroxylamine intermediates in vitro.
9 NAT2 is genetically polymorphic and, depending upon ethnic background, up to 70% of the population may have a slow acetylator phenotype. 18, 25 It would be of interest to establish if the adverse effects of CB1954 in a clinical setting are related to NAT2 phenotype. If so, NAT2 genotyping may assist in predicting toxicity and dose scheduling. 
